Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Recursion Pharmaceuticals Inc Cl A (NQ: RXRX ) 6.400 +0.080 (+1.27%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Recursion Pharmaceuticals Inc Cl A < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Is Recursion Pharmaceuticals a Millionaire-Maker Stock? Today 9:45 EDT In an environment where the typical small biotech name is riskier than not, this one is curiously different. Via The Motley Fool Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 October 31, 2024 The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. Via Benzinga Topics ETFs Stocks Exposures US Equities Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th October 30, 2024 Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia From Recursion Pharmaceuticals Via GlobeNewswire 3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock October 26, 2024 This company stands to benefit from a shifting pharmaceutical industry landscape. Via The Motley Fool Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection October 22, 2024 From Recursion Pharmaceuticals, Inc. Via GlobeNewswire Is Recursion Pharmaceuticals Stock a Buy? September 20, 2024 It largely depends on your investing style. Via The Motley Fool Prediction: These 2 Stocks Could Soar in 2025 October 17, 2024 The key word here is "could." Via The Motley Fool Cathie Wood Is Betting on This AI Stock: Is It a Buy? October 15, 2024 Wood has a stake in this stock, but it's hardly an "all-in" bet. Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip? October 15, 2024 This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing. Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought October 08, 2024 The popular growth investor keeps adding to some of her favorite falling stocks. Via The Motley Fool 2 Artificial Intelligence Stocks That Could Deliver Explosive Gains October 07, 2024 These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence Looking Into Recursion Pharmaceuticals's Recent Short Interest September 16, 2024 Via Benzinga Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals September 04, 2024 Via Benzinga How Is The Market Feeling About Recursion Pharmaceuticals? August 23, 2024 Via Benzinga Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma October 02, 2024 From Recursion Pharmaceuticals, Inc. Via GlobeNewswire 2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk September 29, 2024 The Ark Invest portfolio is known for taking aggressive bets. Via The Motley Fool AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week September 15, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... Via Talk Markets AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th September 10, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... Via Talk Markets These AI-Related Stocks Were Down +10% Week Ending September 6 September 07, 2024 AI-related tech stocks plummeted this week with the August ISM manufacturing index report that figures that came in below consensus expectations raising fears about the strength of the economy and that... Via Talk Markets Topics Economy Exposures Economy Interest Rates Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! September 05, 2024 The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... Via Talk Markets Topics Economy Exposures Economy Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher September 03, 2024 Via Benzinga Exposures Fossil Fuels Nasdaq Dips Over 2%; US Construction Spending Falls In July September 03, 2024 Via Benzinga Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On? September 03, 2024 Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation... Via Benzinga Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 03, 2024 Via Benzinga Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability September 03, 2024 REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... From Recursion Pharmaceuticals, Inc. Via GlobeNewswire Is Recursion Pharmaceuticals a Warren Buffett Stock? August 30, 2024 Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider. Via The Motley Fool Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week August 27, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. Via Talk Markets The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. August 18, 2024 Merging with a former rival will bolster its capabilities. Via The Motley Fool Is Recursion Pharmaceuticals Stock a Buy? August 17, 2024 We'll know a little more about the biotech's prospects in a year and a half. Via The Motley Fool AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD August 14, 2024 The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... Via Talk Markets < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
